| A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function (NCT05440344) | Eli Lilly and Company | 2022-07-05 |
| Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function (NCT04993404) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-08-27 |
| Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants (NCT06190691) | Eli Lilly and Company | 2020-12-18 |
| Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases (NCT04170309) | Advanz Pharma | 2020-03-30 |
| A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function (NCT04226833) | Hoffmann-La Roche | 2020-02-11 |
| Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort (NCT04097704) | Celgene | 2019-09-04 |
| Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency (NCT04147936) | Axcella Health, Inc | 2019-03-30 |
| A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems (NCT03842761) | Boehringer Ingelheim | 2019-03-06 |
| Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite (NCT03968848) | Acerta Pharma BV | 2018-11-12 |
| A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants (NCT03341884) | Genentech, Inc. | 2017-11-09 |
| Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency) (NCT03306667) | Mochida Pharmaceutical Company, Ltd. | 2017-10-06 |
| Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201) (NCT02894385) | Bayer | 2016-09-13 |
| Major Liver Resection: Early Clotting Disorders and Functional Impairment. (NCT02813538) | Hospital General Universitario Gregorio Marañon | 2016-02-05 |
| Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies (NCT02753517) | University Hospital, Lille | 2015-12-08 |
| Mitochondrial Function in Patients With Severe Liver Disease (NCT02457702) | University of Texas Southwestern Medical Center | 2015-10-01 |
| A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment (NCT02387814) | Eli Lilly and Company | 2015-03-01 |
| A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196 (NCT04867941) | Acerta Pharma BV | 2014-10-21 |
| Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers (NCT02191865) | Boehringer Ingelheim | 2014-07-01 |
| A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function (NCT02161224) | Astellas Pharma Europe B.V. | 2013-09-01 |
| A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease (NCT01870388) | Eli Lilly and Company | 2013-06-01 |
| A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment (NCT01836185) | Eli Lilly and Company | 2013-04-01 |
| The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009) (NCT01797536) | Merck Sharp & Dohme LLC | 2013-03-06 |
| A Single Dose Study of LY2605541 in Participants With Liver Impairment (NCT01751399) | Eli Lilly and Company | 2012-12-01 |
| Extracorporeal Photopheresis After Liver Transplant (NCT02090621) | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | 2012-10-01 |
| A Study of LY2140023 in Hepatically-Impaired Participants (NCT01475136) | Denovo Biopharma LLC | 2011-11-01 |
| Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects (NCT01860326) | Debiopharm International SA | 2011-03-01 |
| A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction (NCT01273493) | Janssen Research & Development, LLC | 2010-12-01 |
| Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic Disease (NCT01261923) | University Hospital, Gentofte, Copenhagen | 2010-12-01 |
| Single Dose of 9-cis-retinoic Acid in Hepatic Patients (NCT01891526) | University Hospital, Gentofte, Copenhagen | 2010-12-01 |
| A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function (NCT01186588) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2010-08-01 |
| Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function (NCT01111318) | Boehringer Ingelheim | 2010-07-01 |
| Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017) (NCT01043926) | Merck Sharp & Dohme LLC | 2010-02-22 |
| Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046) (NCT01043887) | Merck Sharp & Dohme LLC | 2010-01-01 |
| Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032 (NCT01019070) | Bristol-Myers Squibb | 2009-12-01 |
| A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function (NCT00969813) | Pfizer | 2009-11-01 |
| Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency (NCT00968591) | Novartis Pharmaceuticals | 2009-11-01 |
| Liver Transplantation and Reticuloendothelial Clearance Capacity (NCT00929032) | University of Edinburgh | 2009-09-01 |
| Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment (NCT00859053) | Bristol-Myers Squibb | 2009-03-01 |
| Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT (NCT00948558) | Huashan Hospital | 2009-03-01 |
| Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects (NCT00805090) | Javelin Pharmaceuticals | 2008-12-01 |
| Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects (NCT02183376) | Boehringer Ingelheim | 2008-07-01 |
| Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics (NCT00692341) | Pfizer | 2008-05-01 |
| Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug (NCT00645021) | Pfizer | 2008-04-01 |
| Preoperative Glucose Infusion: a Novel Strategy to Improve Liver Function After Liver Resection (NCT00623662) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2008-02-01 |
| Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects (NCT00931060) | University of Aarhus | 2007-11-01 |
| Study of Telaprevir in Subjects With Hepatic Impairment (NCT00509210) | Vertex Pharmaceuticals Incorporated | 2007-09-01 |
| Prognostic Impact of Organ Damage in STEMI Patients (NCT02800421) | Inha University Hospital | 2007-01-01 |
| Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function (NCT00416702) | Novartis | 2006-11-01 |
| Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults (NCT00314054) | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-05-01 |
| Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment (NCT02259855) | Boehringer Ingelheim | 2006-01-01 |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function (NCT02170571) | Boehringer Ingelheim | 2005-07-01 |
| A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions (NCT00144248) | Boehringer Ingelheim | 2004-06-25 |
| Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency (NCT02249442) | Boehringer Ingelheim | 2003-10-01 |
| Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers (NCT02265627) | Boehringer Ingelheim | 2000-03-01 |
| Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine (NCT02184091) | Boehringer Ingelheim | 1999-01-01 |